Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Invite your friends, family, colleagues or clients to an exceptional black-tie event in the heart of London. Every ticket, every bid, every moment helps us move closer to a cure.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Join the type 1 diabetes community and come together, raising awareness and vital funds for T1D.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > JDRF UK appoints Terence Lovell as Fundraising and Engagement Director
We are delighted to welcome Terence Lovell as Director of Fundraising and Engagement. Terence has worked in the not-for-profit sector for over 20 years. He built his career at Barnardo’s, Save the Children where he was Deputy Director for Supporters and Communities, and Teach First where he was Director of Development.
Most recently, Terence was Chief Engagement and Marketing Officer at the blood cancer charity Anthony Nolan. He was responsible for increasing voluntary income, building awareness and growth in the stem cell donor register, along with driving digital transformation and organisational strategy development.
Terence has worked in the not-for-profit sector for over 20 years. He built his career at Barnardo’s, Save the Children where he was Deputy Director for Supporters and Communities, and Teach First where he was Director of Development.
He said, “I’m absolutely delighted to be joining JDRF UK as the new Director of Fundraising and Engagement.
“I’m passionate about playing my role in eradicating type 1 diabetes by funding the life-changing research breakthroughs here in the UK and internationally.
“It’s a golden age in type 1 diabetes research progress and I’m excited to be playing such a fundamental part in JDRF’s mission.”
JDRF UK CEO Karen Addington said, “Terence has significant breadth and depth of experience in income generation and supporter engagement.
“We are delighted to welcome him to JDRF UK at this tremendously exciting point in our development where we are so significantly growing in income and impact to prevent, treat and cure type 1 diabetes.”
Breakthrough T1D has helped organise an event hosted by Member of European Parliament Tomislav Sokol titled ‘Accelerating Breakthroughs to Address Unmet Needs in Type 1 Diabetes.’
This study is the largest and most comprehensive to date examining human pancreas tissue for signs of viral infection in people with and without type 1 diabetes (T1D).
People living with type 1 diabetes (T1D) across the UK now have more choice in how to manage their condition, with the mylife CamAPS FX app now available on iPhones.
This charitable pledge by the Bukhman Foundation represents the UK’s largest philanthropic commitment towards funding research to accelerate new treatments and a cure for type 1 diabetes.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.
